Analysts expect Triton International Limited (NYSE:TRTN) to report $0.81 EPS on March, 13.They anticipate $0.60 EPS change or 285.71% from last quarter’s $0.21 EPS. TRTN’s profit would be $65.34M giving it 9.01 P/E if the $0.81 EPS is correct. After having $0.81 EPS previously, Triton International Limited’s analysts see 0.00% EPS growth. The stock decreased 6.74% or $2.11 during the last trading session, reaching $29.18. About 688,100 shares traded or 27.60% up from the average. Triton International Limited (NYSE:TRTN) has risen 101.25% since February 9, 2017 and is uptrending. It has outperformed by 84.55% the S&P500.
Among 8 analysts covering Fresenius Medical (NYSE:FMS), 5 have Buy rating, 0 Sell and 3 Hold. Therefore 63% are positive. Fresenius Medical had 17 analyst reports since July 31, 2015 according to SRatingsIntel. The stock has “Hold” rating by RBC Capital Markets on Monday, September 11. The stock has “Buy” rating by Nomura on Thursday, March 17. The stock has “Overweight” rating by JP Morgan on Monday, January 4. RBC Capital Markets maintained it with “Hold” rating and $4400 target in Wednesday, July 5 report. The stock has “Hold” rating by RBC Capital Markets on Thursday, November 2. The firm has “Hold” rating given on Thursday, October 12 by RBC Capital Markets. The firm has “Sector Perform” rating by RBC Capital Markets given on Wednesday, November 4. The rating was maintained by SunTrust on Wednesday, December 20 with “Buy”. Societe Generale downgraded the shares of FMS in report on Thursday, August 13 to “Buy” rating. The firm earned “Buy” rating on Thursday, November 2 by SunTrust. See Fresenius Medical Care AG & Co. KGAA (NYSE:FMS) latest ratings:
20/12/2017 Broker: SunTrust Rating: Buy New Target: $62.0 Maintain
11/12/2017 Broker: Morgan Stanley Old Rating: Overweight New Rating: Equal-Weight Downgrade
02/11/2017 Broker: RBC Capital Markets Rating: Hold New Target: $50.0 Maintain
02/11/2017 Broker: SunTrust Rating: Buy New Target: $57.0 Maintain
12/10/2017 Broker: RBC Capital Markets Rating: Hold New Target: $44.0 Maintain
11/09/2017 Broker: RBC Capital Markets Rating: Hold New Target: $44.0 Maintain
Triton International Limited engages in the acquisition, leasing, re-leasing, and sale of various intermodal containers and chassis to shipping lines, and freight forwarding companies and manufacturers. The company has market cap of $2.35 billion. It operates in two divisions, Equipment Leasing and Equipment Trading. It has a 13.58 P/E ratio. The firm primarily leases dry freight containers, refrigerated containers, special containers, tank containers, and chassis, as well as manages containers owned by third parties.
Among 2 analysts covering Triton International (NYSE:TRTN), 1 have Buy rating, 0 Sell and 1 Hold. Therefore 50% are positive. Triton International had 4 analyst reports since November 11, 2016 according to SRatingsIntel. The stock of Triton International Limited (NYSE:TRTN) has “Market Perform” rating given on Friday, November 11 by Cowen & Co. The firm earned “Outperform” rating on Tuesday, November 22 by Cowen & Co. Cowen & Co maintained the shares of TRTN in report on Friday, November 10 with “Outperform” rating. The stock of Triton International Limited (NYSE:TRTN) has “Hold” rating given on Monday, May 15 by Wood.
The stock decreased 1.24% or $0.64 during the last trading session, reaching $50.89. About 92,612 shares traded. Fresenius Medical Care AG & Co. KGAA (NYSE:FMS) has risen 11.17% since February 9, 2017 and is uptrending. It has underperformed by 5.53% the S&P500.
Fresenius Medical Care AG & Co. KGaA, a kidney dialysis company, provides dialysis care and related services, and other health care services. The company has market cap of $30.45 billion. It offers dialysis treatment, and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized ESRD patients and for patients suffering from acute kidney failure. It has a 21.78 P/E ratio. The firm also develops, makes, and distributes dialysis products, including hemodialysis machines, peritoneal cyclers, dialyzers, peritoneal solutions, hemodialysis concentrates, solutions and granulates, bloodlines, renal pharmaceuticals, and water treatment systems for the treatment of ESRD; offers renal medications and supplies to patients at homes or to dialysis clinics; and provides vascular, cardiovascular, and endovascular specialty, as well as hospitalist and intensivist, and medical cost management services.